{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:25:51Z","timestamp":1754108751913},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.leukres.2017.10.009","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T15:32:06Z","timestamp":1509118326000},"page":"78-84","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms"],"prefix":"10.1016","volume":"63","author":[{"given":"Maliha","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabbia","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2017.10.009_bib0005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11899-011-0107-9","article-title":"Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?","volume":"7","author":"Kundranda","year":"2012","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"7","key":"10.1016\/j.leukres.2017.10.009_bib0010","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The world health organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2017.10.009_bib0015","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2017.10.009_bib0025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2017.10.009_bib0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood-2002-04-1010","article-title":"Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome\/acute myeloid leukemia","volume":"101","author":"Harada","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2017.10.009_bib0035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/sj.leu.2405078","article-title":"Genetics of therapy-related myelodysplasia and acute myeloid leukemia","volume":"22","author":"Pedersen-Bjergaard","year":"2008","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.leukres.2017.10.009_bib0040","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2009-06-223982","article-title":"AML1\/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms","volume":"114","author":"Ding","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0045","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood-2005-09-3644","article-title":"Rare occurrence of the JAK2 V617F mutation in AML subtypes M5: M6, and M7","volume":"107","author":"Frohling","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2017.10.009_bib0050","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia: but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0055","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2017.10.009_bib0060","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.leukres.2017.10.009_bib0065","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2017.10.009_bib0070","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.leukres.2017.10.009_bib0075","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"p53 lesions in leukemic transformation","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2017.10.009_bib0080","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","article-title":"Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms","volume":"362","author":"Green","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2017.10.009_bib0085","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2017.10.009_bib0090","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0095","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0100","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.0007-1048.2001.03331.x","article-title":"Melphalan treatment in patients with myelofibrosis with myeloid metaplasia","volume":"116","author":"Petti","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"4 Pt 2","key":"10.1016\/j.leukres.2017.10.009_bib0105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"issue":"9","key":"10.1016\/j.leukres.2017.10.009_bib0110","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.10.009_bib0115","first-page":"560","article-title":"Contrasting incidence of acute monocytic and granulocytic leukemias in P32-Treated patients with polycythemia vera and chronic lymphocytic leukemia","volume":"64","author":"Osgood","year":"1964","journal-title":"J. Lab. Clin. Med."},{"issue":"10","key":"10.1016\/j.leukres.2017.10.009_bib0120","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00259-003-1270-6","article-title":"Use and risks of phosphorus-32 in the treatment of polycythaemia vera","volume":"30","author":"Parmentier","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"10.1016\/j.leukres.2017.10.009_bib0125","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2017.10.009_bib0130","first-page":"3630","article-title":"Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia: Italian cooperative study group on myeloid with myeloid metaplasia","volume":"91","author":"Barosi","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2017.10.009_bib0135","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1182\/blood.V92.4.1459","article-title":"Is hydroxyurea leukemogenic in essential thrombocythemia?","volume":"92","author":"Tefferi","year":"1998","journal-title":"Blood"},{"issue":"2 Suppl 3","key":"10.1016\/j.leukres.2017.10.009_bib0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.02.006","article-title":"The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?","volume":"41","author":"Barbui","year":"2004","journal-title":"Semin. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2017.10.009_bib0145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2017.10.009_bib0150","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemianet","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.leukres.2017.10.009_bib0155","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.leukres.2017.10.009_bib0160","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian society of hematology: the Italian society of experimental hematology and the italian group for bone marrow transplantation","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0165","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0170","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/era.11.10","article-title":"Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders","volume":"11","author":"Spivak","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"17","key":"10.1016\/j.leukres.2017.10.009_bib0175","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2017.10.009_bib0180","first-page":"17","article-title":"From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2017.10.009_bib0185","doi-asserted-by":"crossref","first-page":"939","DOI":"10.7326\/0003-4819-148-12-200806170-00221","article-title":"Systematic review: hydroxyurea for the treatment of adults with sickle cell disease","volume":"148","author":"Lanzkron","year":"2008","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.leukres.2017.10.009_bib0190","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2006-12-038968","article-title":"How I treat patients with polycythemia vera","volume":"109","author":"Finazzi","year":"2007","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2017.10.009_bib0195","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12288-014-0354-8","article-title":"Therapy related myelodysplasia\/myeloproliferative neoplasia-unclassified with acute leukemic transformation following Paclitaxel and Carboplatin based chemotherapy in an ovarian cancer patient","volume":"30","author":"Vanajakshi","year":"2014","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"12","key":"10.1016\/j.leukres.2017.10.009_bib0200","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.23505","article-title":"Risk factors for leukemic transformation in patients with primary myelofibrosis","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.leukres.2017.10.009_bib0205","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2017.10.009_bib0210","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1940.1940","article-title":"Survival outcome of patients with acute myeloid leukemia transformed from myeloproliferative neoplasms","volume":"128","author":"Chihara","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2017.10.009_bib0215","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2765","article-title":"Leukaemogenesis: more than mutant genes","volume":"10","author":"Chen","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2017.10.009_bib0220","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2141.2008.07541.x","article-title":"Decitabine is an effective treatment of idiopathic myelofibrosis","volume":"145","author":"Danilov","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2017.10.009_bib0225","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2809.2809","article-title":"Phase II trial of low dose: subcutaneous decitabine in myelofibrosis","volume":"112","author":"Odenike","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0230","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.0007-1048.2001.03319.x","article-title":"Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation","volume":"116","author":"Wang","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"13","key":"10.1016\/j.leukres.2017.10.009_bib0235","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/0008-5472.CAN-07-0572","article-title":"Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis","volume":"67","author":"Shi","year":"2007","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.leukres.2017.10.009_bib0240","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.1158\/0008-5472.CAN-09-1823","article-title":"Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents","volume":"69","author":"Wang","year":"2009","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.leukres.2017.10.009_bib0245","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.leukres.2010.05.008","article-title":"Therapeutic options for patients with myelofibrosis in blast phase","volume":"34","author":"Mascarenhas","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2017.10.009_bib0250","first-page":"202","article-title":"Inhibition of DNA methylation by 5-azacytidine","volume":"84","author":"Jones","year":"1983","journal-title":"Recent Results Cancer Res."},{"issue":"19","key":"10.1016\/j.leukres.2017.10.009_bib0255","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","article-title":"Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)","volume":"116","author":"Thepot","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2017.10.009_bib0260","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.leukres.2012.04.021","article-title":"Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase","volume":"36","author":"Cherington","year":"2012","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.leukres.2017.10.009_bib0265","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood.V96.12.4007","article-title":"Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia","volume":"96","author":"Tefferi","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2017.10.009_bib0270","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2007-08-104745","article-title":"Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies","volume":"112","author":"Marks","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2017.10.009_bib0275","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.leukres.2017.10.009_bib0280","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0300-9084(99)80040-6","article-title":"Involvement of poly(ADP-ribose) polymerase in base excision repair","volume":"81","author":"Dantzer","year":"1999","journal-title":"Biochimie"},{"issue":"10","key":"10.1016\/j.leukres.2017.10.009_bib0285","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1158\/1078-0432.CCR-06-2872","article-title":"Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models","volume":"13","author":"Albert","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.leukres.2017.10.009_bib0290","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888: an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.leukres.2017.10.009_bib0295","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1535-7163.MCT-09-0142","article-title":"Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity","volume":"8","author":"Horton","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.leukres.2017.10.009_bib0300","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1074\/jbc.M111.296475","article-title":"Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes","volume":"287","author":"Patel","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.leukres.2017.10.009_bib0305","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/1078-0432.CCR-16-1274","article-title":"A phase I study of topotecan: carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia","volume":"23","author":"Pratz","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0310","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.beha.2005.07.009","article-title":"Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders","volume":"19","author":"Scott","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2017.10.009_bib0315","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","volume":"19","author":"Aoudjhane","year":"2005","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2017.10.009_bib0320","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0325","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2017.10.009_bib0330","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"22","key":"10.1016\/j.leukres.2017.10.009_bib0335","article-title":"Comparison of allogeneic stem cell transplantation for transformed acute myeloid leukemia derived from MDS, CMML or MPN CMML or MPN. a report of the chronic malignancies working party of EBMT","volume":"128","author":"Kr\u00f6ger","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2017.10.009_bib0340","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.bbmt.2016.09.017","volume":"22","author":"Takagi","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0345","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","article-title":"Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"152","author":"Robin","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2017.10.009_bib0350","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2141.2011.09009.x","article-title":"Risk models predicting survival after reduced-intensity transplantation for myelofibrosis","volume":"157","author":"Alchalby","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2017.10.009_bib0355","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbmt.2009.12.004","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation","volume":"16","author":"Ciurea","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"2","key":"10.1016\/j.leukres.2017.10.009_bib0360","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1365-2141.2001.02584.x","article-title":"Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia","volume":"112","author":"Jurado","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2017.10.009_bib0365","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.bmt.1704657","article-title":"Outcome of allogeneic stem cell transplantation in patients with myelofibrosis","volume":"34","author":"Ditschkowski","year":"2004","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0370","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis: advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"4","key":"10.1016\/j.leukres.2017.10.009_bib0375","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2010.276","article-title":"Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis","volume":"46","author":"Lissandre","year":"2011","journal-title":"Bone Marrow Transplant."},{"issue":"21","key":"10.1016\/j.leukres.2017.10.009_bib0380","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.509.509","article-title":"Phase II study of the JAK2 inhibitor: INCB018424, In patients with refractory leukemias including post-Myeloproliferative disorder (MPD) acute myeloid leukemia (sAML)","volume":"116","author":"Eghtedar","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.leukres.2017.10.009_bib0385","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","article-title":"Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia","volume":"119","author":"Eghtedar","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2017.10.009_bib0390","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1124.1124","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in patients with blast-Phase MPN and post-MPN AML: results of a phase I study (Myeloproliferative disorders research consortium 109 trial)","volume":"128","author":"Rampal","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2017.10.009_bib0395","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4262.4262","article-title":"Phase I\/II study of ruxolitinib (RUX) with decitabine (DAC) in patients with post-Myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML): phase I results","volume":"128","author":"Bose","year":"2016","journal-title":"Blood"},{"issue":"7370","key":"10.1016\/j.leukres.2017.10.009_bib0400","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.leukres.2017.10.009_bib0405","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2017.10.009_bib0410","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-Molecule PROTACS: new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.leukres.2017.10.009_bib0415","article-title":"Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.leukres.2017.10.009_bib0420","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/1078-0432.CCR-11-1541","article-title":"Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells","volume":"17","author":"Fiskus","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.leukres.2017.10.009_bib0425","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.leukres.2017.10.009_bib0430","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.leukres.2017.10.009_bib0435","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.314.314","article-title":"A phase 1\/2 study of RAD001, a mTOR inhibitor, In patients with myelofibrosis: final results","volume":"116","author":"Vannucchi","year":"2010","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.leukres.2017.10.009_bib0440","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1200\/JCO.2008.17.2064","article-title":"Phase I and pharmacokinetic study of YM155: a small-molecule inhibitor of survivin","volume":"26","author":"Tolcher","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.leukres.2017.10.009_bib0445","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1039.1039","article-title":"Phase I study of the novel surivin and cdc2\/CDK1 inhibitor terameprocol in patients with advanced leukemias","volume":"114","author":"Tibes","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2017.10.009_bib0450","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.308.308","article-title":"A phase I study of LBH589: a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-Polycythemia\/Essential thrombocythemia myelofibrosis (Post-PV\/ET MF)","volume":"114","author":"Mascarenhas","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2017.10.009_bib0455","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.100.100","article-title":"A phase 2A study of the histone-Deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms","volume":"112","author":"Rambaldi","year":"2008","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T13:40:38Z","timestamp":1603201238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617305623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":91,"alternative-id":["S0145212617305623"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.10.009","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}